Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Quick facts

Phase 2 pipeline

• Bendamustine-EAM · Oncology
  Bendamustine is an alkylating agent that cross-links DNA to kill rapidly dividing cancer cells, often used in combination with other chemotherapy agents (EAM regimen includes etoposide and cytarabine).
• Consolidation with Brentuximab Vedotin · Oncology
  Antibody-drug conjugate targeting CD30
• Epcoritamab, tafasitamab and lenalidomide
• Induction without Brentuximab Vedotin · Oncology
  This drug induces a response in lymphoma patients without Brentuximab Vedotin.
• Pirtobrutinib and rituximab
• R-MEGACHOP
• RCHOP
• RCOMP
• Rituximab and Bendamustine
• Rituximab, Bendamustine, Mitoxantrone, Dexamethasone
• Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
• subcutaneous Rituximab

Phase 1 pipeline

• Soludomerin · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea portfolio CI brief
• Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea pipeline updates RSS

Related

• Sector hub: All tracked pharma companies